Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF 
inhibitors in the treatment for melanoma. While the two drugs shown to improve 
survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates 
of cSCC are quite different. Drawing upon preclinical and clinical trial data, 
this article discusses the potential factors behind the different cSCC 
incidences reported with the two BRAF inhibitors and provides a strategic 
approach to understand this issue further.